We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.82B
AUM Growth
+$1.31B
Cap. Flow
+$158M
Cap. Flow %
2.03%
Top 10 Hldgs %
19.27%
Holding
869
New
65
Increased
350
Reduced
240
Closed
81

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$43.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$30.4M
3
GILD icon
Gilead Sciences
GILD
+$28.3M
4
BIIB icon
Biogen
BIIB
+$26.7M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$25.2M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$75.2M
2
LOXO
Loxo Oncology, Inc
LOXO
+$28.1M
3
DHR icon
Danaher
DHR
+$27.9M
4
A icon
Agilent Technologies
A
+$26.4M
5
MKC icon
McCormick & Company Non-Voting
MKC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 33.36%
2 Technology 15.96%
3 Financials 11.25%
4 Consumer Discretionary 8.98%
5 Communication Services 7.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TDG icon
476
TransDigm Group
TDG
$70.7B
$2.13M 0.03%
4,685
-366
-7% -$149K
WAT icon
477
Waters Corp
WAT
$37.3B
$2.1M 0.03%
8,335
-2,582
-24% -$588K
S
478
DELISTED
Sprint Corporation
S
$2.1M 0.03%
371,048
+152,448
+70% +$944K
TEF
479
DELISTED
Telefonica
TEF
$2.09M 0.03%
309
-10
-3% -$70
PAYX icon
480
Paychex
PAYX
$43.4B
$2.08M 0.03%
25,908
+276
+1% +$20.4K
DOVA
481
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$2.07M 0.03%
233,200
– –
EXAS
482
DELISTED
Exact Sciences
EXAS
$2.06M 0.03%
23,759
+18,994
+399% +$1.62M
L icon
483
Loews
L
$24.5B
$2.06M 0.03%
42,914
– –
NTLA icon
484
Intellia Therapeutics
NTLA
$1.51B
$2.05M 0.03%
120,000
– –
INFO
485
DELISTED
IHS Markit Ltd. Common Shares
INFO
$2.04M 0.03%
37,433
-7,566
-17% -$396K
QIWI
486
DELISTED
QIWI PLC
QIWI
$2.02M 0.03%
+140,000
New +$2.05M
GS icon
487
Goldman Sachs
GS
$289B
$2.01M 0.03%
10,460
-34,246
-77% -$6.61M
DPZ icon
488
Domino's
DPZ
$11.9B
$2M 0.03%
7,743
+4,322
+126% +$1.12M
LION
489
DELISTED
Fidelity Southern Corporation
LION
$2M 0.03%
72,824
+23,692
+48% +$706K
ESS icon
490
Essex Property Trust
ESS
$19.1B
$1.99M 0.03%
6,877
+639
+10% +$174K
WY icon
491
Weyerhaeuser
WY
$17.6B
$1.98M 0.03%
75,010
-24
-0% -$605
VRSN icon
492
VeriSign
VRSN
$26.3B
$1.95M 0.02%
10,739
-563
-5% -$96.6K
WU icon
493
Western Union
WU
$2.53B
$1.94M 0.02%
42,113
-6,215
-13% -$112K
FTSV
494
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$1.94M 0.02%
120,000
+100,000
+500% +$1.59M
PBCT
495
DELISTED
People's United Financial Inc
PBCT
$1.93M 0.02%
55,163
+3,063
+6% +$51K
BALL icon
496
Ball Corp
BALL
$17.5B
$1.92M 0.02%
33,226
-42,015
-56% -$2.24M
WCN
497
Waste Connections
WCN
$43.6B
$1.92M 0.02%
21,651
– –
GHDX
498
DELISTED
Genomic Health, Inc.
GHDX
$1.92M 0.02%
27,365
+9,616
+54% +$713K
MEOH icon
499
Methanex
MEOH
$4.23B
$1.91M 0.02%
33,615
+543
+2% +$30.6K
TCOM icon
500
Trip.com Group
TCOM
$29B
$1.89M 0.02%
43,245
+30,000
+227% +$1.05M
18 19
20
21 22

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q1 2019 Portfolio in Review

As of Q1 2019, Candriam SCA held 869 positions worth $7.82B, up 20% from $6.51B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Candriam SCA's Q1 2019 filing shows 65 new, 350 increased, 240 reduced and 81 closed positions. Its largest new stake was Baozun: 640,000 shares worth $26.6M. The largest sale was Celgene Corp, an estimated $75.2M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 35% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q1 2019 buy was Baozun: 640,000 shares worth $26.6M.
  • Candriam SCA added most to Merck in Q1 2019, an estimated $43.7M increase.
  • Candriam SCA's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $75.2M.
  • Candriam SCA fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $28.1M.
  • Candriam SCA's ten largest holdings make up 19% of its $7.82B portfolio in Q1 2019.
  • Candriam SCA opened 65 new positions and closed 81 in Q1 2019.
  • Candriam SCA's portfolio value rose 20% quarter-over-quarter to $7.82B.

Based on Candriam SCA's 13F filing for Q1 2019, filed 2 May 2019.